Steven E Collier

US Patent:

20030165563, Sep 4, 2003

Filed:

Dec 20, 2002

Appl. No.:

10/327459

Inventors:

Brendan Murphy - Mystic CT, US
Steven Collier - Berkeley CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

Assignee:

Pfizer Inc.

International Classification:

A61K031/7052
A61K009/20

US Classification:

424/465000, 514/028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

US Patent:

20050287209, Dec 29, 2005

Filed:

Jul 26, 2005

Appl. No.:

11/190393

Inventors:

Brendan Murphy - Quaker Hill CT, US
Steven Collier - Oakland CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

International Classification:

A61K031/7052
A61K009/20

US Classification:

424464000, 514028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

US Patent:

20060024363, Feb 2, 2006

Filed:

Aug 26, 2005

Appl. No.:

11/212332

Inventors:

Brendan Murphy - Mystic CT, US
Steven Collier - Berkeley CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

International Classification:

A61K 9/20
A61K 31/7052

US Classification:

424464000, 514028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

US Patent:

20060024364, Feb 2, 2006

Filed:

Aug 26, 2005

Appl. No.:

11/213022

Inventors:

Brendan Murphy - Mystic CT, US
Steven Collier - Berkeley CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

International Classification:

A61K 31/7052
A61K 9/20

US Classification:

424464000, 514028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.